4//SEC Filing
Dylan-Hyde Tyler 4
Accession 0000899243-18-000074
CIK 0001674416other
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 4:18 PM ET
Size
23.5 KB
Accession
0000899243-18-000074
Insider Transaction Report
Form 4
Dylan-Hyde Tyler
Chief Legal Officer
Transactions
- Sale
Common Shares
2017-12-28$21.75/sh−700$15,225→ 115,204 total - Exercise/Conversion
Common Shares
2017-12-29$12.57/sh+9,070$114,010→ 124,274 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-12-29−6,230→ 58,070 totalExercise: $14.43Exp: 2027-06-15→ Common Shares (6,230 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-12-29−9,070→ 44,263 totalExercise: $12.57Exp: 2026-07-15→ Common Shares (9,070 underlying) - Sale
Common Shares
2017-12-29$21.75/sh−1,070$23,273→ 123,204 total - Sale
Common Shares
2017-12-29$22.68/sh−15,000$340,200→ 100,204 total - Exercise/Conversion
Common Shares
2017-12-28$14.43/sh+700$10,101→ 115,904 total - Exercise/Conversion
Common Shares
2017-12-29$14.43/sh+6,230$89,899→ 121,434 total - Sale
Common Shares
2017-12-29$21.75/sh−6,230$135,503→ 115,204 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-12-28−700→ 64,300 totalExercise: $14.43Exp: 2027-06-15→ Common Shares (700 underlying) - Sale
Common Shares
2017-12-29$23.76/sh−8,000$190,080→ 115,204 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7606 to $23.90, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.6771 to $23.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.
- [F5]This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001682027
Filing Metadata
- Form type
- 4
- Filed
- Jan 1, 7:00 PM ET
- Accepted
- Jan 2, 4:18 PM ET
- Size
- 23.5 KB